tetanus pipeline insight

DelveInsight’s, “Tetanus- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Tetanus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

Tetanus: Understanding

Tetanus: Overview

Tetanus is different from other vaccine-preventable diseases because it does not spread from person to person. The bacteria are usually found in soil, dust, and manure and enter the body through breaks in the skin — usually cuts or puncture wounds caused by contaminated objects. Tetanus is uncommon in the United States, with an average of about 30 reported cases each year. Nearly all cases of tetanus are among people who did not get all the recommended tetanus vaccinations. This includes people who have never received a tetanus vaccine and adults who don’t stay up to date on their 10-year booster shots. Tetanus is an infection caused by a bacterium called Clostridium tetani. Spores of tetanus bacteria are everywhere in the environment, including soil, dust, and manure. The spores develop into bacteria when they enter the body. The spores can get into the body through broken skin, usually through injuries from contaminated objects. Tetanus bacteria are more likely to infect certain breaks in the skin.  These include: Wounds contaminated with dirt, poop (faeces), or spit (saliva), wounds caused by an object puncturing the skin (puncture wounds), like a nail or needle, burns, crush injuries and Injuries with dead tissue. The incubation period — time from exposure to illness — is usually between 3 and 21 days (average 10 days). However, it may range from one day to several months, depending on the kind of wound. Most cases occur within 14 days. In general, doctors see shorter incubation periods with: More heavily contaminated wounds, more serious disease and a worse outcome (prognosis).

 

"Tetanus- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tetanus pipeline landscape is provided which includes the disease overview and Tetanus treatment guidelines. The assessment part of the report embraces, in depth Tetanus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tetanus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Tetanus R&D. The therapies under development are focused on novel approaches to treat/improve Tetanus.

 

Tetanus Emerging Drugs Chapters

This segment of the Tetanus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Tetanus Emerging Drugs

 

GC 3111A : GC Pharma

GC Pharma lead candidate GC 3111A is being developed for the treatment of Tetanus.GC3111A, belongs to the class of bacterial vaccines.It works as immunostimulants.GC 3111A is still in phase II trials for Diphtheria, Pertussis and Tetanus (Prevention) in South Africa.

 

BR TD 1001 : Boryung Biopharma

BR TD 1001 is a lead candidate of Boryung Biopharma, which is being developed for the treatment of tetanus.BR TD 1001, was being investigated in Phase 3 study to evaluate immunogenicity by measuring the seroprotection rate against diphtheria and tetanus at 28 days after vaccination with BR-TD-1001 and Td-pur-inj.

 

TNM 002 : Trinomab Biotech

TNM002 (human monoclonal antibody against tetanus toxin) is being developed for the treatment of Tetanus. TNM 002, works as Bacterial toxin inhibitors. It is Phase I stage of development for the treatment of Tetanus.

Further product details are provided in the report……..

 

Tetanus: Therapeutic Assessment

This segment of the report provides insights about the different Tetanus drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Tetanus

There are approx. 20+ key companies which are developing the therapies for Tetanus. The companies which have their Tetanus drug candidates in the most advanced stage, i.e. phase III include, Boryung Biopharma.

 

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Tetanus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tetanus: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tetanus therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tetanus drugs.

Tetanus Report Insights

• Tetanus Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tetanus Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tetanus drugs?
• How many Tetanus drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tetanus?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tetanus therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tetanus and their status?
• What are the key designations that have been granted to the emerging drugs?